NCT07143331View on ClinicalTrials.gov

A Phase 1 Study to Assess the Safety and Effects of Single and Multiple Doses of KS101 in Healthy Volunteers

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

August 30, 2025

Primary Completion Date

April 1, 2026

Study Completion Date

August 6, 2026

Conditions
Healthy ParticipantsAlzheimer DiseaseChronic Kidney Disease
Interventions
DRUG

Part 1 KS101

Six doses of oral KS101 will be administered to participants.

DRUG

Part 1 Placebo

Six doses of oral matching placebo will be administered to participants.

DRUG

Part 2 with Food

KS101 administered with food

DRUG

Part 2 without food

KS101 administered without food

DRUG

Part 3 KS101

3 multiple doses of KS101

Trial Locations (1)

2031

Scientia Clinical Research, Sydney

All Listed Sponsors
lead

Klotho Sciences Australia Pty Ltd.

INDUSTRY